Mode
Text Size
Log in / Sign up

Prospective observational study of VNS in drug-resistant epilepsy patients with or without prior intracranial surgeryFailed Brain Surgery? This Device Might Still Stop Seizures

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Prior ICSE history does not contraindicate VNS consideration in drug-resistant epilepsy.

This prospective, multicenter, international observational study abstract examines the efficacy and safety of vagus nerve stimulation (VNS) in patients with drug-resistant epilepsy. The cohort included 531 individuals, comparing those with a history of prior intracranial brain surgery for epilepsy (ICSE) against those without such a history. The study assessed seizure reductions at 36 months, responder rates, complete seizure freedom, and adverse events.

At 36 months, the percentage of seizure reductions for all seizures was 76.6% in patients without prior ICSE and 76.3% in those with prior ICSE. For all focal seizures, reductions were 83.3% and 71.8%, respectively, while reductions for all generalized seizures were 77.8% and 76.2%. The 50% responder rate for all seizures was 64.8% and 61.8%, and complete seizure freedom was achieved in 17.9% and 8.8% of patients, respectively. The authors describe these effect sizes as similar between groups.

Implant-related adverse events and serious adverse event rates were similar between the two groups, indicating a consistent safety profile irrespective of the history of ICSE. The study did not report discontinuation rates. The authors note that prior ICSE should not be a contraindication to the consideration of VNS. As an observational study, these findings support clinical decision-making but do not establish causality.

  • VNS works equally well after failed brain surgery.
  • Helps patients with drug-resistant epilepsy seeking relief.
  • Requires implantation, not a new medication pill.

Patients who had brain surgery but still have seizures can still benefit from nerve stimulation therapy.

Imagine spending months recovering from brain surgery, only to still have seizures. It is a heartbreaking feeling for many families. You might feel like there are no options left.

Epilepsy affects millions of people around the world. Sometimes, removing the part of the brain causing seizures does not work. This is called drug-resistant epilepsy. Many patients feel stuck when surgery fails.

Doctors used to think prior surgery made nerve stimulation less effective. They worried the brain was too damaged or scarred. But here is the twist. New data suggests the opposite is true.

Why hope remains possible

Think of the vagus nerve as a main power line to the brain. Vagus nerve stimulation acts like a dimmer switch. It sends gentle pulses to calm overactive brain signals. This helps reduce the frequency of seizures.

Researchers looked at 531 patients over three years. All had drug-resistant epilepsy and received a VNS implant. Some had prior brain surgery, while others did not. They tracked seizure counts and safety closely.

Both groups saw similar drops in seizure frequency. About 60 percent of patients had a 50 percent reduction in seizures. Seizure freedom was reported by nearly 18 percent of those without prior surgery.

The surprising shift

This doesn’t mean this treatment is available yet.

Safety rates were also the same for both groups. There were no extra risks for those who had surgery before. This is a major relief for doctors and patients alike.

Experts say this data opens doors for more treatment choices. It suggests that past surgery should not stop a doctor from offering VNS. It expands the path to care for many patients.

You should talk to your neurologist about all options. VNS is a device, not a pill you take daily. It requires a minor procedure to implant the battery.

What to watch next

This study was observational, not a controlled trial. It relied on real-world data rather than strict testing conditions. Results may vary from person to person.

More research is needed to confirm these long-term results. Doctors will likely update guidelines based on this evidence. Approval processes will take time before widespread use.

Study Details

Sample sizen = 531
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Objective: Vagus nerve stimulation (VNS) is an established neuromodulation therapy used in the management of drug-resistant epilepsy (DRE), or when other intracranial surgical modalities have not reduced seizure burden. We evaluated whether prior intracranial surgery for epilepsy influences safety and effectiveness outcomes with adjunctive VNS, using real-world data from the CORE-VNS study. Methods: CORE-VNS (NCT03529045), a prospective, multicenter, international observational study, was designed to collect data on seizure and non-seizure outcomes in patients with DRE treated with VNS. Participants were identified as having or not having undergone prior intracranial brain surgery for epilepsy (ICSE) and received an initial VNS implant. Baseline seizure frequency data and patient-reported outcome measures were collected at 3, 6, 12, 24, and 36 months. This analysis compared the baseline data for VNS therapy and safety outcomes at 36 months. Results: Among 531 participants implanted with VNS, prior ICSE was performed in 84. Median percentage seizure reductions at 36 months for all seizures (76.6% and 76.3%), all focal seizures (83.3% and 71.8%), and all generalized seizures (77.8% and 76.2%) were found to be similar between those without and with a history of ICSE, respectively. The 50% responder rate for all seizures reported at baseline was similar, 64.8% and 61.8%, in both groups and complete seizure freedom was reported by 17.9% and 8.8%, respectively. Implant-related adverse events (AE) and serious AE rates were similar between groups. Conclusion: VNS was associated with clinically meaningful seizure reductions and showed a consistent safety profile irrespective of the history of ICSE. Prior ICSE should not be a contraindication to the consideration of VNS.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.